We are live on ! Find out more
A

Abingworth Portfolio holdings

AUM $307M
1-Year Est. Return 93.47%
This Fund
S&P 500
This Quarter Est. Return
+6.83%
1 Year Est. Return
+93.47%
3 Year Est. Return
+184.38%
5 Year Est. Return
+342.7%
10 Year Est. Return
–
AUM
$261M
AUM Growth
+$149M
Cap. Flow
+$141M
Cap. Flow %
54.06%
Top 10 Hldgs %
99.24%
Holding
15
New
1
Increased
–
Reduced
3
Closed
1

Top Buys

Rank Stock Value
1
PSNL icon
Personalis
PSNL
+$154M

Top Sells

Rank Stock Value
1
CHMA
Chiasma, Inc. Common Stock
CHMA
+$10.5M
2
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$1.39M
3
RLM
Realm Therapeutics plc American Depositary Shares
RLM
+$988K
4
OCGN icon
Ocugen
OCGN
+$255K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PSNL icon
1
Personalis
PSNL
$1.41B
$148M 56.74%
+5,449,294
New +$154M
CRSP icon
2
CRISPR Therapeutics
CRSP
$4.76B
$55M 21.11%
1,171,268
– –
SIEN
3
DELISTED
Sientra, Inc.
SIEN
$14.7M 5.64%
239,084
– –
AVDR
4
DELISTED
Avedro, Inc Common Stock
AVDR
$14.1M 5.4%
719,402
– –
SLNO
5
DELISTED
Soleno Therapeutics
SLNO
$12.1M 4.66%
311,285
– –
VRNA
6
DELISTED
Verona Pharma
VRNA
$4.54M 1.74%
901,943
– –
PRTK
7
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$4.12M 1.58%
1,041,131
– –
CHMA
8
DELISTED
Chiasma, Inc. Common Stock
CHMA
$3.56M 1.36%
478,206
-1,602,389
-77% -$10.5M
SYRE icon
9
Spyre Therapeutics
SYRE
$8.65B
$1.64M 0.63%
9,620
– –
OBSV
10
DELISTED
ObsEva SA Ordinary Shares
OBSV
$985K 0.38%
87,999
– –
CBAY
11
DELISTED
Cymabay Therapeutics
CBAY
$937K 0.36%
131,036
– –
TARA icon
12
Protara Therapeutics
TARA
$229M
$851K 0.33%
50,447
– –
SRRA
13
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$121K 0.05%
5,417
-28,709
-84% -$1.39M
OCGN icon
14
Ocugen
OCGN
$454M
$84K 0.03%
7,111
-22,519
-76% -$255K
RLM
15
DELISTED
Realm Therapeutics plc American Depositary Shares
RLM
– –
-255,371
Closed -$988K

Similar funds

AAM
Arabesque Asset Management London, United Kingdom $296M AUM 15.19% 1-Year Est. Return
EP
Equius Partners Novato, California $324M AUM 8.27% 1-Year Est. Return
LDFR
Lehman & Derafelo Financial Resources Media, Pennsylvania $337M AUM 8.16% 1-Year Est. Return
MPAM
Monarch Partners Asset Management Boston, Massachusetts $339M AUM 2.52% 1-Year Est. Return
MAG
Mass Ave Global New York $342M AUM 20.58% 1-Year Est. Return
CDIA
Capital Directions Investment Advisors Atlanta, Georgia $268M AUM 20.15% 1-Year Est. Return
GTCM
Gyon Technologies Capital Management Denville, New Jersey $267M AUM 11.62% 1-Year Est. Return
ACMV
August Capital Management VII Palo Alto, California $265M AUM 26.86% 1-Year Est. Return

Abingworth's Q2 2019 Portfolio in Review

As of Q2 2019, Abingworth held 15 positions worth $261M, up 133% from $112M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Abingworth deployed $141M of net new capital in Q2 2019, opening 1 new position. Its largest new stake was Personalis: 5,449,294 shares worth $148M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Chiasma, Inc. Common Stock, an estimated $10.5M trimmed.

  • Abingworth's largest Q2 2019 buy was Personalis: 5,449,294 shares worth $148M.
  • Abingworth's biggest Q2 2019 reduction was Chiasma, Inc. Common Stock, cutting an estimated $10.5M.
  • Abingworth fully exited Realm Therapeutics plc American Depositary Shares in Q2 2019, selling an estimated $988K.
  • Abingworth's ten largest holdings make up 99% of its $261M portfolio in Q2 2019.
  • Abingworth opened 1 new position and closed 1 in Q2 2019.
  • Abingworth's portfolio value rose 133% quarter-over-quarter to $261M.

Based on Abingworth's 13F filing for Q2 2019, filed 14 Aug 2019.